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Abstract 1 
Quantifying HIV-1 transmission risk per act of anal intercourse (AI) is important for HIV-1 prevention. 2 
We updated previous reviews by searching Medline and Embase to 02/2018. We derived pooled 3 
estimates of receptive AI (URAI) and insertive AI (UIAI) risk unprotected by condoms using random 4 
effects models. Subgroup analyses were conducted by gender, study design, and whether 5 
antiretroviral treatment (ART) had been introduced by the time of the study.  6 
Two new relevant studies were identified, one of which met inclusion criteria, adding three new 7 
cohorts and increasing number of individuals/partnerships included from 1869 to 14,277. Four 8 
studies, all from high-income countries, were included. Pooled HIV-1 risk was higher for URAI 9 
(1.25%,95%CI 0.55-2.23%,N=5,I2=87%) than UIAI (0.17%,95%CI 0.09-0.26%,N=3,I2=0%). The sole 10 
heterosexual URAI estimate (3.38%,95%CI 1.85-4.91%), from a study of 72 women published in a 11 
peer-reviewed journal, was significantly higher than the MSM pooled estimate (0.75%,95%CI 0.56-12 
0.98%,N=4,p<0.0001) and higher than the only other heterosexual estimate identified (0.4%,95%CI 13 
0.08-2.0%, based on 59 women, excluded for being a pre-2013 abstract). Pooled per-act URAI risk 14 
varied by study design (retrospective-partner studies: 2.56%,95%CI 1.20-4.42%,N=2 (one MSM, one 15 
heterosexual); prospective studies: 0.71,95%CI 0.51-0.93%,N=3 MSM, p<0.0001). URAI risk was 16 
lower for studies conducted in the ART era (0.75%,95%CI 0.52-1.03%) than pre-ART (1.67%,95%CI 17 
0.44-3.67%) but not significantly so (p=0.537).  18 
Prevention messages must emphasise that HIV-1 infectiousness through AI remains high, even in the 19 
ART era. Further studies, particularly among heterosexual populations and in resource-limited 20 
settings, are required to elucidate whether AI risk differs by gender, region and following 21 
population-level ART scale-up. 22 
Keywords: HIV, anal intercourse, transmission probability, infectivity, review, meta-analysis, 23 
heterosexual, MSM, antiretroviral therapy 24 
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Introduction 25 
Anal intercourse (AI) drives HIV-1 epidemics among men-who-have-sex-with-men (MSM), and 26 
numerous studies have demonstrated that substantial proportions of heterosexual populations also 27 
practise AI1, 2, potentially making it an important source of heterosexual HIV-1 transmission3. 28 
Quantifying the role of AI in HIV-1 epidemics is important for effective targeting of safe sex 29 
messages, for developing and implementing HIV-1 prevention technologies, and to inform 30 
mathematical models. Two previously published systematic reviews and meta-analyses have only 31 
included four studies providing estimates of the probability of HIV-1 transmission per AI act 32 
unprotected by condoms 4, 5.  33 
Baggaley et al derived the first pooled receptive AI unprotected by condoms (URAI) per-act 34 
estimates in 2010 (1.37%, 95% confidence interval[95%CI] 0.20-2.54%)5. Patel et al4 updated the 35 
review to February 2012, and derived a similar pooled estimate to Baggaley et al despite excluding a 36 
study included in Baggaley et al6 and incorporating one new study (1.38%, 95%CI 1.02-1.86%)5, 7. 37 
Patel also reported a pooled estimate for insertive AI unprotected by condoms (UIAI): 0.1% (95%CI 38 
0.0-0.3%). However, since their search, additional per-act estimates derived from large HIV-1 cohort 39 
datasets have been published8, 9. Given the scarce data on per-act AI HIV risk, it is important to 40 
update pooled estimates in light of new data, to reduce uncertainty and provide more reliable 41 
estimates to address public health questions and for use in models.  42 
Addition of further data may enable evaluation of how HIV-1 infectiousness through AI varies by 43 
gender of participants, by ART use in the general population, region and other study characteristics. 44 
For example, recent evidence from animal studies suggests increased susceptibility of male rhesus 45 
macaques to HIV-1 acquisition following intrarectal challenge, compared to females (Diane Bolton, 46 
personal communication). 47 
Our aim was to revise pooled estimates of URAI and insertive AI unprotected by condoms (UIAI) per-48 
act HIV-1 transmission risk through incorporation of new data. We aimed to assess whether the 49 
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addition of new data leads to significantly different pooled estimates of AI per-act risk; to evaluate 50 
the robustness of pooled estimates through sensitivity analysis; and to conduct subgroup analysis to 51 
investigate the influence of: 1) ART use among study participants or their partners; 2) gender; 3) 52 
region; and 4) study design. 53 
 54 
Methods 55 
The systematic review and meta-analysis were conducted in accordance with the PRISMA 56 
statement10. 57 
Search strategy  58 
We conducted literature searches to identify new studies reporting data on per-act HIV-1 59 
transmission risk through anal intercourse (AI) published since searches originally performed by 60 
Baggaley et al5 (searched to September 2008), and Patel et al4 (searched to February 2012). Our 61 
search was harmonised to ensure inclusion of terms employed previously4, 5. We used the following 62 
search string: (HIV OR HIV infections OR human immunodeficiency virus OR AIDS) AND (disease 63 
transmission OR infectious OR infectivity OR infectiousness OR transmissibility OR contact OR 64 
contacts OR per-contact OR per-act OR effectiveness) AND (sexual OR heterosexual OR homosexual 65 
OR coital OR intercourse OR anal). We searched Medline (Ovid), Embase (Ovid), CINAHL (EbscoHost), 66 
Web of Science, Global Health, and the Cochrane Library for studies published February 2012 to 67 
February 2018 inclusive. See Supplementary Material for further search details.  68 
Unlike Baggaley et al5, which focused on transmission risk estimates in the absence of ART, we also 69 
included studies where ART was likely used by a proportion of study participant partners. This 70 
change of inclusion criterion necessitated searching the exclusion lists of Baggaley et al5 to ensure no 71 
studies were excluded based on ART use. We defined ART use to include therapeutic use by index 72 
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(i.e. initially infected) partners, or pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis 73 
(PEP) use by their (initially uninfected) partners.  74 
Study selection 75 
Inclusion criteria were randomised controlled trials, longitudinal studies (prospective or 76 
retrospective) or other empirical observational studies that directly reported estimates of per-act 77 
HIV-1 transmission risk through AI. We excluded studies that did not stratify AI risk, receptive versus 78 
insertive. Abstracts pre-2013, studies using sample sizes less than 10, and estimates derived from 79 
dynamic transmission modelling studies fitted to empirical HIV-1 prevalence curves, were excluded. 80 
While we included studies where study populations included individuals using ART, we aimed to 81 
include “real life studies” only, and so excluded studies where successful, suppressive ART of index 82 
partners was an inclusion criterion. Abstracts and other unpublished data older than five years were 83 
excluded because they were unlikely to result in peer-reviewed publication. There was no restriction 84 
by study year, region, or language of publication. AI per-act estimates included in previous 85 
systematic reviews4, 5, which we refer to as “original estimates”, were included if they fulfilled the 86 
current inclusion criteria.  87 
Data extraction 88 
Study review was conducted independently by two separate authors (RFB and BNO). Data were 89 
extracted on the following study and participant characteristics: region, study design, study dates, 90 
gender (MSM or heterosexual study population), sample size, statistical method of estimating per-91 
act risk, information on current and history of sexually transmitted infections (STIs), proportion of 92 
the study partner population using therapeutic ART and stage of HIV-1 infection of infected partners, 93 
condom use, intravenous drug use and ART use (PrEP or PEP). Discrepancies were resolved by 94 
consensus. 95 
Statistical methods 96 
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We performed random-effects inverse-variance meta-analysis11 on arcsin-transformed study 97 
estimates, which were back-transformed to the original scale to produce pooled estimates for per-98 
act risk of HIV-1 transmission through URAI and UIAI. We presented available study estimates and 99 
pooled URAI and UIAI estimates in forest plots.  100 
Meta-regression and subgroup analysis were used to explore potential sources of heterogeneity: 101 
gender; study design e.g. retrospective-partner study, prospective cohort of individuals; and ART use 102 
among partners. We assessed the robustness of pooled estimates and the influence of each 103 
individual study using leave-one-out sensitivity analysis (i.e., an influence analysis11). We also 104 
assessed the influence of relaxing our inclusion criteria to include Halperin et al (0.4%,95%CI 0.08-105 
2.0%, excluded for being unpublished data pre-20136). Heterogeneity across study estimates was 106 
assessed using I2 statistics. Analysis was performed using R version 3.4.212 and the metafor package.  107 
Results 108 
Search results  109 
Of 5336 unique studies published from February 2012 to February 2018 that we identified in our 110 
online searches, 4985 were excluded for non-relevance based on title, and 349 excluded based on 111 
abstract or full text. Two new articles directly reported per-act HIV-1 transmission probability 112 
estimates8, 9. No study had been excluded from our previous review based on ART use. Figure 1 113 
illustrates the study selection procedure.  114 
Studies included in each systematic review  115 
Table 1 summarises per-act URAI and UIAI transmission risk estimates and study characteristics for 116 
estimates included in Baggaley et al 20105, Patel et al4 and the current analysis. Detailed study 117 
characteristics are shown in Table S1, Supplementary Material. Data from 14,227 and 14,000 118 
individuals/partnerships reported in the included studies were used to inform URAI and UIAI pooled 119 
estimates, respectively, compared to 1869 individuals/partnerships included in Baggaley et al5). 120 
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Of the two newly-identified studies8, 9, Scott et al8 was preferentially included. Smith et al9 used data 121 
from EXPLORE13 and VAX 00414 studies, while Scott et al8 additionally included Jumpstart15 and 122 
HIVNET Vaccine Preparedness Study (VPS)16, 17 data. Furthermore, Smith et al9 did not account for 123 
risk factors such as ethnicity and drug use, or for heterogeneity in per-act risk, as Scott did. Scott et 124 
al8 results also superseded and improved upon Vittinghoff et al18 estimates, which were conducted 125 
by the same research group and included the same Jumpstart study data. Vittinghoff et al18 data are 126 
therefore excluded. Halperin et al6, included by Baggaley et al5, was excluded for being a pre-2013 127 
abstract. Further details of the advantages of Scott et al methodology, together with further 128 
information regarding excluded studies, are provided in Supplementary Material. 129 
Study characteristics  130 
Five URAI per-act study estimates reported by four studies7, 8, 19, 20 and three UIAI estimates reported 131 
by two studies7, 8 were included in the current analysis (Figure 1). Scott et al8 provided independent 132 
estimates for pre-highly active antiretroviral therapy (HAART, hereafter referred to as ART: study 133 
data from 1992-1995) and early ART (study data from 1995-2003) eras, for both URAI and UIAI, 134 
because they combined data from four cohorts13-17.  135 
Data collection occurred between 1987 and 2007, although the earliest included publication did not 136 
state study dates19. URAI study estimates used data from Australia (N=17), the US (N=38, 19) and one 137 
multi-European country study20 (Table 1). UIAI study estimates used data from Australia (N=17) and 138 
the US (N=219). All but one included study estimate (Leynaert et al20, URAI) used data from MSM 139 
populations (Figure 2). Two URAI study estimates were from retrospective-partner studies19, 20; the 140 
remaining three used data from prospective cohorts of individuals7, 8.  141 
 Three URAI study estimates used face-to-face interview (FTFI) data (8, 20 and pre-ART19), a third used 142 
FTFI combined with telephone interviewing7, and Scott et al’s8 early ART study estimate combined 143 
data gathered using FTFI (VAX00414 and VPS16, 17) and audio computer-assisted self-interview (ACASI) 144 
(Explore13). For UIAI, all three study estimates were from prospective studies and data were 145 
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collected using FTFI (pre-ART19), FTFI plus telephone interview7 and FTFI plus ACASI combined (early 146 
ART8).  147 
No studies reported on ART use of index partners. These data were not available from cohorts of 148 
individuals because they cannot be collected using this design7, 8. Authors discussed plausible ART 149 
coverage among infected partners but did not attempt to adjust estimates to account for ART use. 150 
Jin et al cited national data that 70% of Australian MSM used ART, and 75% of those had 151 
undetectable viral load7. For their early ART era estimates, Scott et al cited national data that only 152 
around 80% of those infected were aware of their status, and only 30% were virally suppressed, and 153 
that these levels were probably even lower during study periods. ART use was also not collected by 154 
retrospective-partner studies19, 20. Leynaert et al (retrospective-partner) reported that ART use data 155 
were not collected, but the study was conducted 1987-1992 and so use was minimal20. Similarly, 156 
DeGruttola et al (retrospective-partner) was published in 198919. Therefore ART use was minimal, 157 
likely 0%, in 3 of 5 (19, 20 and pre-ART8) and 1 (pre-ART8) of 3 URAI and UIAI study estimates, 158 
respectively. The remaining two studies were classed as having >0% ART use7, 8. Although no 159 
included studies reported any information on PEP or PrEP use by study participants, its use is 160 
expected to be very low, given the dates of data collection (all before 2007). 161 
Study size varied considerably. Retrospective-partner studies enrolled 15519 and 7220 couples, while 162 
cohorts followed between 14277 and 4581 (EXPLORE13, included as part of Scott et al8) individuals. 163 
Number of AI acts with a partner appeared to vary considerably between individuals in the same 164 
study, with infectiousness similarly heterogeneous: Jin et al noted that 12 seroconversions in their 165 
cohort occurred as a result of <10 unprotected AI acts, while six men did not seroconvert despite 166 
reporting a total of 502 URAI acts with ejaculation7. Similarly, DeGruttola reported that 12 men 167 
reported >100 URAI acts with HIV-1-infected partners without seroconverting, while five men 168 
seroconverted after ≤10 such exposures to their infected partner and <3 partners outside the main 169 
relationship19. 170 
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Meta-analysis results 171 
The updated pooled estimate of per-act URAI HIV-1 risk of 1.25% (95%CI 0.55-2.23%,N=5, I2=87%)7, 8, 172 
19, 20) was considerably and statistically significantly higher (p=0.0026) and more heterogeneous than 173 
the UIAI risk (0.17%, 95%CI 0.09-0.26%, I2=0%,N=37, 8). Pooled and study estimates are shown in 174 
Figure 2. 175 
Subgroup analysis   176 
Table 2 shows the results of the subgroup analysis. The pooled per-act URAI HIV-1 risk was 177 
significantly lower for MSM (0.75% 95%CI 0.56-0.98%,N=4) than the sole heterosexual population 178 
estimate (3.38% 95%CI 1.85-4.91%,N=1) (p<0.0001). However, relaxing inclusion criteria to include 179 
Halperin et al6 (0.4% 95%CI 0.08-2.0%), one of just two identified estimates from heterosexual 180 
populations, excluded for being an abstract pre-2013, reduced the pooled heterosexual URAI 181 
estimate to 1.57% (95%CI 0.00-5.87%,N=2,I2=91%) which was no longer significantly different from 182 
the MSM estimate (p=0.370, Figure S1). MSM per-act estimates for both URAI and UIAI showed 183 
relatively little heterogeneity (I2<0.1%).  184 
Pooled per-act URAI risk from studies where ART was likely to have been used by >0% of sexual 185 
partners was lower than half (0.75%,95%CI 0.52-1.03%N=2) that without ART use (1.67%,95%CI 186 
0.44-3.67%,N=3) but this difference was not significant (p=0.537). Per-act UIAI risks were similar by 187 
ART use (0.14%,95%CI 0.04-0.29% for 0% use vs. 0.18%,95%CI 0.09-0.31% for >0% use, p=0.955). 188 
When assessed in multivariate meta-regression analysis, only study design was (borderline) 189 
significantly associated with magnitude of URAI transmission risk (p=0.055), accounting for >99% of 190 
the heterogeneity across study estimates (R2=99.9%). Meta-regression analysis could not be 191 
undertaken for UIAI given the small number of estimates (N=3, all from MSM populations). 192 
Sensitivity analysis   193 
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 In  the leave-one-out sensitivity analysis, only the omission of the heterosexual URAI estimate from 194 
Leynaert et al20 among heterosexual couples substantially reduced heterogeneity (I2 reduced from 195 
87% to 0%), producing an all-MSM pooled URAI estimate (0.75%, 95%CI 0.56-0.98%) (Figure S1). 196 
Adding the Halperin et al6 study estimate did not substantially influence the URAI pooled estimate 197 
(1.10%,95%CI 0.50-1.94%,I2=85%, Figure S1). The pooled UIAI estimate was also not affected by any 198 
individual study estimate because study estimates were remarkably homogeneous (Figure 2, I2=0). 199 
 200 
Discussion 201 
Our updated review incorporates recently-published study estimates which strengthen the analysis 202 
and robustness of pooled per-act risk estimates by greatly increasing the number of included 203 
individuals (data from 14,227 individuals/partnerships, compared to 1869 individuals/partnerships in 204 
Baggaley et al5). Our results highlight that risk of HIV-1 transmission through AI remains high 205 
(1.25%,95%CI 0.55-2.23%,N=5 for URAI; 0.17%,95%CI 0.09-0.26%,N=3 for UIAI), and raises the 206 
question of whether HIV risk during URAI is higher for women than MSM, also highlighting the lack 207 
of data from resource-limited settings.  208 
Our new pooled estimate is slightly lower than the previous pooled URAI estimates by Baggaley et 209 
al5 and Patel et al4, and a slight, nonsignificant increase on the previous pooled UIAI estimate 210 
reported by Patel et al4. We have explored sources of heterogeneity as far as possible, given the few 211 
included study estimates. In fact, URAI and UIAI estimates from MSM study populations were 212 
remarkably homogeneous (I2=0%). It is unclear whether gender or study design accounted for the 213 
heterogeneity across all URAI study estimates, but even after omitting the highest URAI estimate 214 
(i.e., the sole heterosexual estimate20, see Figure S1), the estimate of HIV-1 transmission risk through 215 
URAI remained high (0.75%,95%CI 0.56-0.98%). Even considering only study estimates which were 216 
conducted since the introduction of ART, risk remained nearly 10-fold riskier than unprotected 217 
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receptive vaginal intercourse (VI): URAI 0.75%,95%CI 0.52-1.03% vs. unprotected receptive VI: 218 
0.08%,95%CI 0.06-0.11%21. UIAI risk in the ART era is more than four-fold riskier than insertive VI 219 
(0.18%,95%CI 0.09-0.31% vs. 0.04%,95%CI 0.01-0.14%21).  220 
It is unclear why the Leynaert et al URAI risk among females was so high (3.38%, 95%CI 1.85-221 
4.91%20). All studies were conducted in industrialised countries, so difference by region is unlikely. 222 
Heterosexual study participants reported monogamy and no STIs. However, a large proportion of 223 
index cases (65% of the entire sample) were infected by intravenous drug use, so while their sexual 224 
partners reported no such use, it is possible that they underreported HIV-1 exposure and acquired 225 
HIV-1 via this route. Leynaert et al was a retrospective-partner study, and in multivariate meta-226 
regression, study design explained a larger fraction of the variation across URAI estimates than 227 
gender, so the apparent difference by gender may be confounded by study design. HIV risk during 228 
URAI is especially uncertain because the only other identified URAI estimate among females, which 229 
was excluded for being a pre-2013 abstract, provided a markedly lower estimate than Leynaert et al 230 
(0.4% 95%CI 0.08-2.0%): it is in fact lower than all the five included URAI study estimates. This clouds 231 
the picture of potential differential risk by gender. The sample sizes of both Leynaert and Halperin 232 
were low (n<80), and given heterogeneity in infectiousness between individuals and by stage of HIV-233 
1 infection25, the widely different estimates may be due to chance (95%CIs are wide and 234 
overlapping: 1.85-4.91%20 and 0.08-2.0%6). The lack of study design detail for the Halperin abstract 235 
makes it difficult to postulate reasons for the low estimate. However, our main results, based on the 236 
a priori exclusion of Halperin et al, mean we cannot exclude the possibility that women have an 237 
intrinsically higher URAI HIV-1 acquisition risk than men. This warrants further research, given its 238 
implication for HIV-1 prevention. There may exist underlying biological differences between the 239 
rectal compartments of males and females, rendering women more susceptible to infection. For 240 
example, there may be sex hormone differences, which alter rectal mucosal immunology and 241 
enhance susceptibility26. However, there has been little research conducted in this area to date, and 242 
recent evidence from animal studies suggested an opposite effect (Diane Bolton, person 243 
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communication). Alternatively, variation in sexual practices by gender may play a role. MSM may be 244 
more likely to anticipate receptive AI and therefore prepare to reduce the likelihood of trauma (such 245 
as use of lubricants, cleansing the colon). Qualitative research has suggested that heterosexual AI 246 
often occurs without the explicit prior consent of women27, 28. 247 
Our meta-regression found the pooled URAI risk among studies conducted in the ART era, when 248 
there was likely to be >0% ART use among sexual partners of study participants, was less than half 249 
that from pre-ART studies, but this difference failed to reach statistical significance, probably partly 250 
because of the small number of estimates and also the variability across estimates in the pre-ART era 251 
(from 0.60%8 to 3.38%20). For both URAI and UIAI, Scott et al pre-ART and early ART era per-act study 252 
estimates were very similar. Scott et al explained this lack of a significant association by suggesting  253 
that a relatively low proportion of infected MSM were on ART and had a suppressed viral load during 254 
the years in which data were collected. However, Jin et al7 URAI estimates were also high, and 255 
similar to Baggaley et al5 2010’s pooled estimate (without ART use), despite the likely high ART use in 256 
the Australian study population. In fact, omitting the high heterosexual URAI estimate from Leynaert 257 
et al20 makes pre-ART and ART era URAI estimates more comparable: 1.00% (95%CI 0.22-2.33%) and 258 
0.75% (95%CI 0.52-1.03%), respectively.  259 
 260 
However, as Jin and Scott et al followed individuals rather than couples over time, information on 261 
infection status, current ART use and viral load of each sexual partner of each study participant was 262 
missing: data that are required to control for ART use adequately. While evidence shows that HIV-263 
infected individuals with ART-mediated viral suppression do not transmit HIV-122-24, our findings 264 
demonstrate that HIV-1 infectiousness through AI remains high, indicating that many HIV-infected 265 
individuals practising condomless AI are not on effective ART and remain infectious. 266 
With ART coverage having continued to increase, now taken at earlier stages of HIV-1 infection and more 267 
tolerable regimens increasing levels of adherence, and with the advent of PrEP, it is expected that any 268 
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future AI HIV-1 infectiousness studies would find further, significant reductions in infectiousness 269 
estimates. However, HIV-infected MSM engaging in nondisclosing (not disclosing their HIV status to their 270 
partner), condomless AI have been found to be less ART-adherent and more likely to have unsuppressed 271 
HIV31 and so it is important to collect further data to monitor whether these population-level AI HIV-1 272 
infectiousness estimates continue to decline over time. 273 
There are some limitations to our findings, mainly due to scarcity of data. The few study estimates 274 
prevent us exploring the sources of heterogeneity in greater depth. Only one heterosexual study 275 
estimate was included, so it is difficult to know if differences in infectiousness by gender are real or 276 
confounded by study design. Included estimates were from only two study types: retrospective-277 
partner and prospective studies of individuals. Both have advantages and disadvantages. For 278 
example, prospective studies are less likely to experience recall bias and therefore estimating 279 
numbers of sex acts may be more precise than retrospective studies. Recruiting individuals is easier 280 
than recruiting couples, providing larger sample sizes. Partner studies provide more reliable data on 281 
index cases, particularly regarding HIV-1 status, and in theory on their patterns of ART use. Studies of 282 
individuals rely on participants’ perceptions of the status of their sexual partners. However, couples 283 
may be more likely to underreport sexual partners outside the main relationship because of social 284 
desirability bias. Leynaert et al only reported from monogamous couples20, but all other study 285 
estimates included participants reporting multiple partners and multiple sexual behaviours. It can be 286 
challenging to estimate transmission risks using such data, especially where the HIV-1 infection and 287 
ART use status of sexual partners cannot be known with certainty: there are a lot of unknowns which 288 
must be accounted for. Different studies have used different statistical techniques to attempt this. 289 
All but one study used FTFI to gather sexual behaviour data, which may lead to social desirability 290 
bias32. These limitations may over- or underestimate per-act risk, and together with the small 291 
number of studies identified, and the variation in methods of data analysis, mean we recommend 292 
further data gathering using more confidential techniques such as ACASI, and analysis using 293 
standardised statistical methods, to increase comparability of studies and robustness of pooled 294 
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estimates. Publication bias and selective reporting are likely to be low, because these studies are not 295 
assessing significance or effectiveness outcomes. This bias could be investigated using funnel plots if 296 
more study estimates became available. 297 
In conclusion, current evidence suggests that practising unprotected AI continues to confer a high 298 
risk of HIV-1 transmission, particularly URAI, even in the ART era. More research is needed as 299 
important knowledge gaps regarding HIV-1 risk during AI remain. Given the high HIV-1 transmission 300 
risk associated with AI, it is remarkable that more research has not been conducted to evaluate if AI 301 
transmissibility differs by gender, high- and low-income countries and following ART scale-up at the 302 
population level. Standardised methods should be used to aid comparability between studies, and 303 
longitudinal studies reporting HIV transmission rates should be encouraged to use these methods to 304 
additionally report per-act estimates. Even today it continues to be important to design safe sex 305 
messaging that promotes the use of condoms in addition to interventions such as PrEP and other 306 
biotechnologies to prevent HIV-1 transmission through AI for both MSM and heterosexual 307 
populations. 308 
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Tables 
Table 1 Summary of per-act anal intercourse HIV-1 transmission probability studies included in meta-analyses reported by Baggaley et al 20105, Patel et 
al4, and the current analysis. Reasons for study exclusion are provided, where applicable. 
Study Population, sample 
size, setting 
Design. Study dates Per-act estimate, % 
(95%CI) 
 Included in:  
 Baggaley et al 2010 Patel et al 2014 Current analysis 
URAI 
DeGruttola et al 198919 132 MSM (some 
infected, some 
uninfected) plus 155 
sexual partners, US 
Retrospective-partner, 
study dates not stated 
0.5-3.0a    
Leynaert et al 199820 72heterosexual couples 
(male index) practising 
AI, Europe 
Retrospective-partner, 
1987-1992 
3.38 (1.85-4.91)    
Vittinghoff et al 199918 1583 MSM, US Prospective cohort of 
individuals, 1992-1994 
0.82 (0.24-2.76)   × 
Supersededc 
Halperin et al 2002 (abstract)6 
plus S.C. Shiboski (personal 
communication, 2003) 
59 heterosexual couples 
(male index), US 
Retrospective-partner, 
participants recruited 
1985-1986 
0.4 (0.08-2.0)b  × 
Estimate interpreted 
as a relative risk 
× 
Abstract pre-2013 
Jin et al 20107 1427 MSM, Australia Prospective cohort of 
individuals, 2001-2007 
0.91d (0.41-2.07) × 
Data not yet published 
 
 
 
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Study Population, sample 
size, setting 
Design. Study dates Per-act estimate, % 
(95%CI) 
 Included in:  
 Baggaley et al 2010 Patel et al 2014 Current analysis 
Scott et al 20148 MSM, US 
Pre-ART N=1813 c 
Early ART N=10,760f 
Four prospective cohorts 
of individuals: Jumpstart 
1992-199515, EXPLORE 
1999-200313, VAX 004 
1998-200214, VPS 1995-
199916, 17 
 
0.60e 
0.73f 
 
(0.34-1.09) 
(0.45-0.98) 
× 
Data not yet published 
× 
Not includedg 
 
Smith et al 20159 3490 MSM, US 
 
 
 
Two prospective cohorts 
of individuals: EXPLORE 
1999-200313, VAX 004 
1998-200214 
1.11h 
0.41i 
(0.75-1.62) 
(0.30-0.55) 
× 
Data not yet published 
× 
Data not yet 
published 
× 
Study data reported by 
Scott et al 2014 8 
UIAI   
Vittinghoff et al 199918 1583 MSM, US Prospective cohort of 
individuals, 1992-1994 
0.06 (0.02-0.19) × 
Estimate is per partner of 
HIV-1 positive or 
unknown serostatus 
 × 
Estimate is per partner of 
HIV-1 positive or unknown 
serostatus; supersededc 
Jin et al 20107 1427 MSM, Australia Prospective cohort of 
individuals, 2001-2007 
0.16 (0.05-0.31) × 
Data not yet published 
  
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Study Population, sample 
size, setting 
Design. Study dates Per-act estimate, % 
(95%CI) 
 Included in:  
 Baggaley et al 2010 Patel et al 2014 Current analysis 
Scott et al 20148 MSM, US 
Pre-ART N=1813c 
Early ART N=10,760f 
Four prospective cohorts 
of individuals: Jumpstart 
1992-199515, EXPLORE 
1999-200313, VAX 004 
1998-200214, VPS 1995-
199916, 17 
 
0.14e 
0.22f 
 
(0.04-0.29) 
(0.05-0.39) 
× 
Data not yet published 
× 
Not includedg 
 
Smith et al 20159 3490 MSM, US Two prospective cohorts 
of individuals: EXPLORE 
1999-200313, VAX 004 
1998-200214 
0.27h 
0.20i 
(0.18-0.41) 
(0.15-0.27) 
× 
Data not yet published 
× 
Data not yet 
published 
× 
Study data reported by 
Scott et al 2014 8 
NS – not stated. 
a Range rather than 95%CI reported by publication. 
b Range rather than 95%CI. 
c Estimate superseded by reanalysis of the dataset reported in Scott et al 20148. 
d Jin et al7 published per-act risk with ejaculation taking place inside the rectum (1.43%, 95%CI 0.48-2.85%) and with withdrawal prior to ejaculation (0.65%, 95%CI 0.15-1.53%). Per-act estimate 
regardless of when ejaculation occurred was reported in Patel et al4, obtained from study authors (James Jansson, personal communication).   
e Data taken from the pre-ART era (estimates use data from the Jumpstart study15). 
f Data taken from the early ART era (estimates use data from the EXPLORE13, VAX 00414, and VPS16, 17 studies). 
g Data mentioned in text but not included in meta-analysis 
h Data taken from the EXPLORE study13, restricted to study participants reporting never using condoms. 
i Data taken from the VAX 004 study14, restricted to study participants reporting never using condoms.  
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Table 2 Subgroup analysis: meta-analytic pooled per-act HIV-1 transmission probability estimates for URAI 
and UIAI stratified by population subgroup (heterosexual and MSM), study design (retrospective-partner 
and prospective cohort of individuals) and plausible extent of ART use by sexual partners (0% versus >0%). 
Estimate type Pooled estimate, % 
(95%CI) 
Pa I2,b, (%) N References p-valuea  
URAI       
Gender      
   Women 3.38 (1.85-4.91) 1.000 0.0% 1 20  
   MSM 0.75 (0.56-0.98) 0.278 <0.1% 4 7, 8, 19c p<0.0001 
Study design       
   Retrospective-partner 2.56 (1.20-4.42) 0.1296 56.5% 2 19, 20  
   Prospective cohort of individuals 0.71 (0.51-0.93) 0.722 0.0% 3 7, 8c p<0.0001 
Plausible extent of ART use by sexual partners      
   0% 1.67 (0.44-3.67) <0.0001 87.6% 3 8, 19, 20d  
   >0% 0.75 (0.52-1.03) 0.650 0.0% 2 7, 8d p=0.537 
Pooled estimate 1.25 (0.55-2.23) 0.0002 87.3% 5 7, 8, 19, 20c  
UIAIe       
Plausible extent of ART use by sexual partners      
   0% 0.14 (0.04-0.29) 1.000 0.0% 1 8  
   >0% 0.18 (0.09-0.31)  0.604 0.0% 2 7, 8c P=0.955 
Pooled estimate 0.17 (0.09-0.26) 0.7716 0.0% 3 7, 8c  
ART – antiretroviral treatment; N – number of study estimates; NA – not applicable; P – P-value; Q – heterogeneity statistic; UIAI – 
unprotected insertive anal intercourse; URAI – unprotected receptive anal intercourse. 
a “P” is the p-value for heterogeneity of the pooled estimate; “p-value” is the metaregression p-value defining the significance of the 
difference in pooled estimates between the two subgroups. 
b I2 is calculated as described in Higgins et al33. I2 lies between 0 and 100%; 0% indicates no observed heterogeneity and larger values 
show increasing heterogeneity. 
c Two URAI and UIAI estimates were provided by Scott et al8, using data from studies conducted in the pre-ART and early ART eras. 
d Scott et al’s8 pre-ART estimates are classed as likely 0% ART use; its early ART estimates are classed as >0% use.  
e All UIAI study estimates used data from prospective cohorts of individuals from MSM populations and so subgroup analysis could not 
be conducted gender or design. 
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Figure legends 
Figure 1 Flowchart summary of the literature search, comprising an update search from 2012 to 
February 2018 and a catch-up search to ensure the pre-2012 search included the same search terms 
as the updated search. “Original estimates” refers to studies included in either previous review4, 5. 
ART – antiretroviral therapy; CINAHL – Cumulative Index to Nursing and Allied Health Literature; UIAI 
– unprotected insertive anal intercourse; URAI – unprotected receptive anal intercourse.  
Figure 2 Forest plot of studies estimating per-act HIV-1 transmission probability through anal 
intercourse. “Original estimates” refers to studies included in either previous review4, 5. 
